How to Schedule Patients Receiving OnabotA for OAB to Maximize Adherence

Systematic elimination of barriers to retreatment is a defining feature of Steven Bernstein, MD's approach to onabotulinumtoxinA (Botox) management. Chief among these strategies is proactive scheduling: Every patient in his practice departs with the next treatment appointment already on the calendar. A brief virtual follow-up visit is scheduled at 2 weeks post-procedure—or an in-person visit for first-time recipients—to assess response, at which point the subsequent treatment is booked. Bernstein acknowledges that retreatment timing may be adjusted based on early symptom recurrence or continued efficacy, but the scheduled appointment serves as a default anchor that removes the activation barrier of patient-initiated rebooking.

Bernstein frames proactive scheduling as consistent with contemporary patient expectations across service industries, noting that appointment-forward models are standard in settings ranging from dental practices to barbershops. In the context of a chronic, relapsing condition such as OAB, where persistence on therapy has historically been suboptimal, this structural approach operationalizes continuity of care. He views the combination of a streamlined, minimally burdensome injection protocol with a scheduled retreatment framework as synergistic: reducing the procedural hassle factor lowers the threshold for patients to keep—and continue booking—appointments.

Bernstein's overarching message for practicing urologists who may be skeptical of departing from the standard 20-site protocol is one of pragmatic, evidence-informed evolution. He encourages colleagues to consider that published procedural standards represent starting points rather than fixed end points, and that patient-centered refinement—applied methodically and transparently—can yield meaningful improvements in both experience and outcomes. Clinicians interested in adopting a reduced-site approach may begin at whichever point along the spectrum they are comfortable with, whether that is 10 sites, 3 sites, or a single injection. Bernstein reiterates that single-site injection is off-label, and he welcomes peer engagement with the data and the clinical rationale that supports this evolving practice.